Role of Alzheimer's disease models in designing and testing experimental therapeutics

Drug Discovery Today: Disease Models

Volumn 2, Issue 4, 2005, Pages 305-312

  Savonenko, Alena V ^a   Laird, Fiona M ^a   Troncoso, Juan C ^a   Wong, Philip C ^a   Price, Donald L ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN ANTIBODY; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; AMYLOID PROTEIN; BETA SECRETASE; BETA SECRETASE INHIBITOR; GAMMA SECRETASE; GAMMA SECRETASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; NOTCH1 RECEPTOR; PROTEIN ANTIBODY; TAU PROTEIN;

AGE; ALZHEIMER DISEASE; AMNESIA; BRAIN HEMORRHAGE; CLINICAL TRIAL; COGNITIVE DEFECT; DISEASE MODEL; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; ENCEPHALOMYELITIS; ENZYME ACTIVITY; ENZYME INHIBITION; FAMILIAL AMYLOIDOSIS; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; IMMUNOTHERAPY; MENINGOENCEPHALITIS; NONHUMAN; PASSIVE IMMUNIZATION; PATHOGENESIS; PREDICTION; PROTEIN SYNTHESIS; REVIEW; SIDE EFFECT;

EID: 30444441141     PISSN: 17406757     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddmod.2005.11.006     Document Type: Review

References (40)

1. C.H. Kawas et al. Epidemiology of dementia and Alzheimer's disease In R.D. Terry et al. (eds) Alzheimer's Disease 1999 Lippincott Williams & Wilkins 347-378
2. S.S. Sisodia et al. Amyloidogenesis in Alzheimer's disease and animal models In F.E. Bloom and D.J. Kupfer (eds) Psychopharmacology: The Fourth Generation of Progress 1995 Raven Press 445-490
3. A. Goate et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease Nature 349 1991 704-706
4. Wong, P.C. et al. (2005) Neurobiology of Alzheimer's disease. In Basic Neurochemistry (7th edn), pp. 567-601, Lippincott Williams & Wilkins
5. F.M. LaFerla et al. Alzheimer's disease: Abeta, tau and synaptic dysfunction Trends Mol. Med. 11 2005 170-176
6. K.H. Ashe Mechanisms of memory loss in Abeta and tau mouse models Biochem. Soc. Trans. 33 2005 591-594
7. D.L. Price et al. Mutant genes in familial Alzheimer's disease and transgenic models Annu. Rev. Neurosci. 21 1998 479-505
8. P.C. Wong et al. Genetically engineered mouse models of neurodegenerative diseases Nat. Neurosci. 5 2002 633-639
9. B. Caughey et al. Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders Annu. Rev. Neurosci. 26 2003 267-298
10. Y. Gong et al. Alzheimer's disease-affected brain: Presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss Proc. Natl. Acad. Sci. U S A 100 2003 10417-10422
11. D.R. Borchelt et al. Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins Neuron 19 1997 939-945
12. M.C. Herzig et al. Abeta is targeted to the vasculature in a mouse model of hereditary cerebral hemorrhage with amyloidosis Nat. Neurosci. 7 2004 954-960
13. D.J. Selkoe Alzheimer's disease is a synaptic failure Science 298 2002 789-791
14. V.M. Lee et al. Neurodegenerative tauopathies Annu. Rev. Neurosci. 24 2001 1121-1159
15. K. Santacruz et al. Tau suppression in a neurodegenerative mouse model improves memory function Science 309 2005 476-481
16. S. Oddo et al. Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome Neuron 43 2004 321-332
17. K.H. Ashe Learning and memory in transgenic mice modeling Alzheimer's disease Learn. Mem. 8 2001 301-308
18. J.P. Cleary et al. Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function Nat. Neurosci. 8 2005 79-84
19. A.V. Savonenko et al. Normal cognitive behavior in two distinct congenic lines of transgenic mice hyperexpressing mutant APP SWE Neurobiol. Dis. 12 2003 194-211
20. A.V. Savonenko et al. Episodic-like memory deficits in the APPswe/PS1dE9 mouse model of Alzheimer's disease: Relationship to beta-amyloid and neurotransmitter abnormalities Neurobiol. Dis. 18 2005 602-617
21. D. Morgan et al. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease Nature 408 2000 982-985
22. R.B. DeMattos et al. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease Proc. Natl. Acad. Sci. U S A 98 2001 8850-8855
23. J.C. Dodart et al. Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model Nat. Neurosci. 5 2002 452-457
24. D. Schenk et al. Current progress in beta-amyloid immunotherapy Curr. Opin. Immunol. 16 2004 599-606
25. F. Bard et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease Nat. Med. 6 2000 916-919
26. L.A. Kotilinek et al. Reversible memory loss in a mouse transgenic model of Alzheimer's disease J. Neurosci. 22 2002 6331-6335
27. D.M. Walsh et al. The role of cell-derived oligomers of Abeta in Alzheimer's disease and avenues for therapeutic intervention Biochem. Soc. Trans. 33 2005 1087-1090
28. D.M. Hartley et al. Protofibrillar intermediates of amyloid beta-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons J. Neurosci. 19 1999 8876-8884
29. M.T. Jensen et al. Lifelong immunization with human beta-amyloid (1-42) protects Alzheimer's transgenic mice against cognitive impairment throughout aging Neuroscience 130 2005 667-684
30. Jankowsky, J.L. et al. (2005) Persistent amyloidosis following suppression of Abeta production in a transgenic model of Alzheimer's disease. PLoS Med. 2, e355.
31. J.M. Orgogozo et al. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization Neurology 61 2003 46-54
32. R. Furlan et al. Vaccination with amyloid-beta peptide induces autoimmune encephalomyelitis in C57/BL6 mice Brain 126 2003 285-291
33. M. Pfeifer et al. Cerebral hemorrhage after passive anti-Abeta immunotherapy Science 298 2002 1379
34. D.M. Wilcock et al. Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage J. Neuroinflamm. 1 2004 24
35. H. Cai et al. BACE1 is the major beta-secretase for generation of Abeta peptides by neurons Nat. Neurosci. 4 2001 233-234
36. Y. Luo et al. Mice deficient in BACE1, the Alzheimer's beta-secretase, have normal phenotype and abolished beta-amyloid generation Nat. Neurosci. 4 2001 231-232
37. Laird, F.M. et al. (2005) BACE1, a major determinant of selective vulnerability of the brain to Ab amyloidogenesis, is essential for cognitive, emotional and synaptic functions. J. Neurosci. 25
38. Y.M. Kuo et al. The evolution of A beta peptide burden in the APP23 transgenic mice: Implications for A beta deposition in Alzheimer disease Mol. Med. 7 2001 609-618
39. B. Solomon et al. Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer beta-amyloid peptide Proc. Natl. Acad. Sci. U S A 93 1996 452-455
40. D.M. Wilcock et al. Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition J. Neurosci. 24 2004 6144-6151